Us Congress House Bill HB4053

Us Congress 2023-2024 Regular Session

• Introduced: 6/13/23
• Refer: 6/13/23
• Refer: 6/16/23

Caption

Studying Suboxone Act

Impact

The potential impact of HB 4053 on state laws is significant. By facilitating a review of buprenorphine-naloxone combination products, the bill aims to ensure that regulations reflect the latest scientific knowledge and medical practices. This can result in a more suitable classification of these medications, potentially making them more accessible for healthcare providers and patients seeking treatment for opioid addiction. The changes may lead to an increase in the use of these products if they are reclassified, thereby impacting public health positively.

Summary

House Bill 4053, also known as the 'Studying Suboxone Act', aims to initiate a comprehensive review of the scheduling of buprenorphine-naloxone combination products under the Controlled Substances Act. This bill assigns the Secretary of Health and Human Services the responsibility to assess current scientific and medical evaluations regarding these products and to recommend any necessary updates on their scheduling. Such assessments are crucial given the increasing opioid crisis and the need for effective treatment options.

Contention

Notable points of contention around HB 4053 may arise from differing perspectives on addiction treatment and drug regulation. Advocates for addiction treatment are likely to support the bill, viewing the reassessment of buprenorphine-naloxone products as a step towards improving patient access to necessary medications. However, opponents may express concerns regarding the potential for misuse and addiction, emphasizing the need for strict controls and monitoring of any changes in scheduling. The balance between increasing access to treatment and ensuring public safety will be a central theme in discussions surrounding this legislation.